Travere Therapeutics (TVTX) Return on Capital Employed (2013 - 2026)
Travere Therapeutics (TVTX) posted Return on Capital Employed of 12.55% for Q1 2026, up 17.71% on a QoQ basis from 15.25% in Q4 2025, and up 4587.0% year-over-year from 0.27% in Q1 2025.
Travere Therapeutics (TVTX) Return on Capital Employed (2013 - 2026) Analysis & Trends
Travere Therapeutics' Return on Capital Employed history runs 14 years deep, the most recent figure standing at 12.55% for Q1 2026.
- Quarterly Return on Capital Employed rose 4587.0% year-over-year to 12.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.55% (up 4587.0% YoY) and the FY2025 annual result came in at 14.29%, up 5170.0% from the prior year.
- Return on Capital Employed was 12.55% for Q1 2026 at Travere Therapeutics, up from 15.25% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 12.55% in Q1 2026 and bottomed at 105.8% in Q3 2024.
- A 5-year average of 54.65% and a median of 57.39% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 4681 bps — and 2025, when it jumped 8368 bps.
- Travere Therapeutics' Return on Capital Employed stood at 57.39% in 2022, then fell by 7 bps to 61.32% in 2023, then tumbled by 52 bps to 92.92% in 2024, then surged by 84 bps to 15.25% in 2025, then increased by 18 bps to 12.55% in 2026.
- Business Quant data shows TVTX's Return on Capital Employed at 12.55% in Q1 2026, 15.25% in Q4 2025, and 22.13% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -12.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.55% |
| Dec 31, 2025 | -15.25% |
| Sep 30, 2025 | -22.13% |
| Jun 30, 2025 | -47.50% |
| Mar 31, 2025 | -58.42% |
| Dec 31, 2024 | -92.92% |
| Sep 30, 2024 | -105.80% |
| Jun 30, 2024 | -81.01% |
| Mar 31, 2024 | -77.76% |
| Dec 31, 2023 | -61.32% |
| Sep 30, 2023 | -58.99% |
| Jun 30, 2023 | -58.22% |
| Mar 31, 2023 | -56.61% |
| Dec 31, 2022 | -57.39% |
| Sep 30, 2022 | -51.13% |
| Jun 30, 2022 | -39.31% |
| Mar 31, 2022 | -32.77% |
| Dec 31, 2021 | -30.60% |
| Sep 30, 2021 | -35.99% |
| Jun 30, 2021 | -33.54% |